Business Wire

INSTITUTO-COORDENADAS

23.6.2020 18:13:05 CEST | Business Wire | Press release

Share
Barcelona Stands out in European Research Into Fighting Covid-19

In the socioeconomic recovery of Europe’s main cities following the effects of the Covid-19 pandemic, a commitment to healthcare, innovation and medical research is a key element. In that regard, Barcelona and the surrounding area play a European leadership role, uniting a powerful healthcare field with a high quality scientific research network. And according to the initial conclusions of a study by Instituto Coordenadas, the city’s response to Covid-19 is an example of public-private partnership.

The response of the healthcare sector, ensuring Barcelona is a safe city, combines with the Catalan capital’s research efforts over several decades and its strength in recruiting talent for innovation and research in biotechnology and health. The city’s hospital network, for instance, has made great strides in both medicine and research during the crisis. Some of the main achievements in that regard include the work of Hospital Clínic, and its partnership with the US-based MIT research team in particular, and the Vall d’Hebron University Hospital, which has been congratulated by the World Health Organization (WHO) for managing the fight against the pandemic. Another example of Barcelona’s dominant position lies in the work of the SciTech DiploHub, an initiative that has succeeded in bringing together the field of international scientific diplomacy.

Barcelona’s public-private scientific ecosystem has also been at work during the Covid-19 threat, with around 20 initiatives placing Catalonia’s capital at the forefront in the fight against the pandemic. Examples go from top level clinical trials, such as the one carried out by Germans Trias i Pujol Research Institute (IGTP) to stop those with the virus spreading it further, to IQS’s efforts to find an inhibitor for attacking one of the receptors of Covid-19. Most recently, the expertise of three doctors from Barcelona’s ISGlobal played a key role in redressing the errors relating to the effectiveness of hydroxychloroquine as regards Covid-19, and there is also the example of the work being carried out into new treatments for eliminating cytokine storms.

Another development that has put Barcelona on the front line has been the global partnership between the city’s six cutting-edge science centres, 110 pharmaceutical companies – with their long-standing relationship with the city – and biotech businesses and start-ups based at the Barcelona Science Park (PCB). The aim of the alliance is to secure an effective antiretroviral drug for fighting Covid-19, vaccines and more effective rapid diagnostic tests.

PCB, with its 2,800 professionals, was Spain’s first science park and is home to IRB Barcelona, which is one of the research centres selected by the European Union to identify an effective vaccine, new treatments and better rapid diagnostic tests. In fact, of the 17 projects selected in Europe, five come from Barcelona and the surrounding area.

The fight against the virus has seen the whole of the local research network entering into partnership. For instance, the Barcelona Supercomputing Center (BSC) has made its Mare Nostrum supercomputer available to researchers so they can fight the pandemic using artificial intelligence and bioinformatics.

In short, this array of alliances has put Barcelona in a position of excellence on the European map of efforts to fight Covid-19.

ABOUT INSTITUTO COORDENADAS DE GOBERNANZA Y ECONOMIA APLICADA

The institute develops thought and undertakes research into the interaction between governance and applied economics in order to make constructive and decisive progress in three fundamental issues: social wellbeing, economic progress and environmental sustainability. This takes place in a context of development and evolution, unprecedented since the end of the 18th century and the beginning of the 19th century with the industrial revolution. Faithful to its founding principles of independence, non-partisanship and plurality, the institute is a proactive leader of the fusion between the essence and innovation of economic liberalisation as the best model for tackling the challenge of the present and the future in Spain, Europe and the world.

Further information: www.institutocoordenadas.com

NOTE: The information contained in this press release is a public interest summary from reports and studies based on analysis and research; expert working groups and sessions; and/or production of scientific articles by Instituto Coordenadas de Gobernanza y Economía Aplicada. The original and complete documents are for internal use and are the sole property of Instituto Coordenadas de Gobernanza y Economía Aplicada.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release

- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p

Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere

Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release

Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta

Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release

We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi

Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release

Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye